Photographer: Chris J. Ratcliffe/Bloomberg.
See Original Article

It’s not looking good for Corbus Pharmaceuticals and the autoimmune disease treatment lenabasum. Corbus disclosed another in a long string of failures for the synthetic oral cannabinoid type 2 agonist, this time in a late-stage trial in the rare autoimmune …
See Original Article

The digital media company, which will merge with a publicly listed shell company in what is known as a SPAC deal, also lined up about $150 million in debt financing.
See Original Article

Demonstrators attempt to breach the U.S. Capitol in Washington, DC, on Jan. 6. Photographer: Victor J. Blue/Bloomberg. Multiple House and Senate
See Original Article

“One of the main complaints we heard from accountants was in continuing to receive correspondence from the IRS that doesn't acknowledge prior
See Original Article